MeSH term
Frequency | Condition_Probility | Adolescent | 50 | 0.0 |
Adult | 240 | 0.0 |
Aged | 41 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Animals | 33 | 0.0 |
Female | 181 | 0.0 |
Humans | 527 | 0.0 |
Male | 310 | 0.0 |
Middle Aged | 149 | 0.0 |
Retrospective Studies | 15 | 0.0 |
Treatment Outcome | 9 | 0.0 |
*Apoptosis | 3 | 0.0 |
Cell Line | 15 | 0.0 |
Cells, Cultured | 20 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Mice | 7 | 0.0 |
Models, Biological | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Rats | 10 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 215 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 113 | 0.0 |
Algorithms | 2 | 0.0 |
Comparative Study | 67 | 0.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Reference Values | 10 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Bicuspid | 5 | 50.0 |
Dental Bonding/methods | 2 | 100.0 |
Dental Stress Analysis/methods | 2 | 100.0 |
*Light | 6 | 17.0 |
Microscopy, Electron, Scanning | 4 | 1.0 |
*Resin Cements | 3 | 50.0 |
Tensile Strength | 4 | 21.0 |
Analysis of Variance | 19 | 0.0 |
Color | 2 | 7.0 |
Drug Combinations | 2 | 0.0 |
Incisor | 3 | 23.0 |
Lasers | 3 | 2.0 |
Light | 12 | 5.0 |
Statistics, Nonparametric | 6 | 0.0 |
Tooth Bleaching/*methods | 2 | 50.0 |
Bisphenol A-Glycidyl Methacrylate/chemistry/radiation effects | 3 | 100.0 |
Dental Cavity Preparation/classification | 3 | 60.0 |
Dental Leakage/*classification | 3 | 100.0 |
Temperature | 3 | 0.0 |
Thermodynamics | 3 | 0.0 |
Water | 2 | 3.0 |
Hardness | 3 | 33.0 |
Materials Testing | 14 | 20.0 |
Polymers/chemistry | 6 | 24.0 |
Statistics | 6 | 1.0 |
Surface Properties | 8 | 4.0 |
Time Factors | 30 | 0.0 |
Water/chemistry | 2 | 5.0 |
*Dental Veneers | 2 | 66.0 |
Equipment Design | 4 | 3.0 |
Lighting/instrumentation | 2 | 100.0 |
Composite Resins/chemistry | 2 | 20.0 |
*Dental Equipment | 6 | 100.0 |
Dentin/*physiology | 2 | 40.0 |
Regression Analysis | 7 | 0.0 |
Infant, Newborn | 6 | 0.0 |
T-Lymphocytes/*immunology | 8 | 0.0 |
Hela Cells | 4 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Dental Stress Analysis | 4 | 28.0 |
Halogens | 6 | 85.0 |
Longitudinal Studies | 5 | 0.0 |
*Orthodontic Brackets | 4 | 66.0 |
Quartz | 3 | 100.0 |
Resin Cements/*radiation effects | 4 | 100.0 |
Stainless Steel | 2 | 40.0 |
Survival Analysis | 8 | 0.0 |
Xenon | 4 | 100.0 |
Dentin-Bonding Agents/chemistry | 3 | 60.0 |
Lighting/*instrumentation | 6 | 100.0 |
Polymers/chemistry/radiation effects | 3 | 100.0 |
Cytoskeletal Proteins/*genetics | 2 | 1.0 |
Molecular Sequence Data | 14 | 0.0 |
Nerve Tissue Proteins/*genetics | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
AIDS-Related Complex/diagnosis | 3 | 60.0 |
Acquired Immunodeficiency Syndrome/diagnosis | 2 | 10.0 |
Adaptation, Psychological | 3 | 6.0 |
CD4 Lymphocyte Count | 8 | 0.0 |
Base Sequence | 9 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Chi-Square Distribution | 3 | 0.0 |
*Mutation | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Composite Resins/*chemistry | 4 | 33.0 |
Resin Cements/*chemistry | 3 | 42.0 |
Technology, Dental/*instrumentation | 2 | 100.0 |
Genotype | 2 | 0.0 |
HIV Core Protein p24/blood | 6 | 6.0 |
HIV-1/*genetics | 2 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
*Dental Restoration, Permanent | 2 | 50.0 |
Glass Ionomer Cements/chemistry | 2 | 28.0 |
Antibody Specificity | 7 | 0.0 |
Disease Progression | 8 | 0.0 |
Viral Load | 2 | 0.0 |
Range of Motion, Articular | 2 | 8.0 |
Sensitivity and Specificity | 5 | 0.0 |
Bisphenol A-Glycidyl Methacrylate/radiation effects | 2 | 100.0 |
Composite Resins/*radiation effects | 3 | 100.0 |
Molecular Structure | 2 | 0.0 |
Signal Processing, Computer-Assisted | 2 | 4.0 |
Bisphenol A-Glycidyl Methacrylate | 2 | 100.0 |
Composite Resins | 2 | 40.0 |
*Dentin-Bonding Agents | 2 | 50.0 |
*Post and Core Technique | 2 | 50.0 |
English Abstract | 32 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Infant | 18 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Escherichia coli | 3 | 0.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Signal Transduction/drug effects | 2 | 0.0 |
AIDS-Related Complex/*drug therapy/immunology | 9 | 64.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/immunology | 9 | 21.0 |
*CD4 Lymphocyte Count | 2 | 0.0 |
Drug Administration Schedule | 6 | 0.0 |
Drug Resistance, Microbial | 2 | 1.0 |
Drug Therapy, Combination | 12 | 0.0 |
Follow-Up Studies | 25 | 0.0 |
Leptin | 2 | 1.0 |
Paraventricular Hypothalamic Nucleus/drug effects/metabolism | 2 | 50.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 11 | 0.0 |
Radioimmunoassay | 8 | 0.0 |
Receptors, Androgen/*metabolism | 2 | 1.0 |
Ceramics/*chemistry | 2 | 50.0 |
Pilot Projects | 4 | 0.0 |
Resin Cements/chemistry | 4 | 33.0 |
Biopsy | 10 | 0.0 |
Lymph Nodes/*pathology | 3 | 3.0 |
Cloning, Molecular | 6 | 0.0 |
Gene Expression | 2 | 0.0 |
HIV-1/*isolation & purification | 3 | 3.0 |
Biological Markers | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*immunology | 54 | 23.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
HIV-1/*immunology | 8 | 1.0 |
Immunophenotyping | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 3 | 0.0 |
Acquired Immunodeficiency Syndrome/drug therapy | 3 | 9.0 |
HIV Infections/*drug therapy | 6 | 2.0 |
Zidovudine/administration & dosage/*therapeutic use | 3 | 10.0 |
AIDS-Related Complex/physiopathology | 3 | 75.0 |
HIV Seropositivity/*physiopathology | 3 | 37.0 |
Lung/*physiopathology | 2 | 10.0 |
Respiratory Function Tests | 2 | 1.0 |
Dose-Response Relationship, Drug | 11 | 0.0 |
Genes, env | 2 | 3.0 |
Electromyography | 3 | 1.0 |
Body Weight | 6 | 0.0 |
Didanosine/*administration & dosage/adverse effects/therapeutic use | 2 | 66.0 |
*HIV-1 | 23 | 2.0 |
Pancreatitis/chemically induced | 5 | 45.0 |
Zidovudine/*therapeutic use | 12 | 7.0 |
Acquired Immunodeficiency Syndrome/drug therapy/*immunology | 3 | 21.0 |
Flow Cytometry | 8 | 0.0 |
HIV-1 | 4 | 2.0 |
Neutrophils/*immunology | 3 | 1.0 |
*Phagocytosis | 2 | 1.0 |
Zidovudine/therapeutic use | 5 | 2.0 |
Child | 40 | 0.0 |
DNA, Viral/*analysis | 3 | 3.0 |
RNA, Viral/*analysis | 3 | 5.0 |
Risk Factors | 32 | 0.0 |
Motion Perception/*physiology | 2 | 13.0 |
Double-Blind Method | 12 | 0.0 |
Isoelectric Focusing | 2 | 0.0 |
AIDS-Related Complex/immunology | 23 | 62.0 |
HIV Seropositivity/diagnosis/*immunology | 2 | 40.0 |
Acid Etching, Dental | 2 | 20.0 |
Dental Bonding/*instrumentation | 2 | 100.0 |
Linear Models | 2 | 0.0 |
Maxilla | 2 | 18.0 |
Dental Bonding | 3 | 50.0 |
Dental Veneers | 2 | 33.0 |
HIV Antibodies/*analysis | 7 | 33.0 |
Immunoglobulin G/analysis | 6 | 1.0 |
Acyclovir/administration & dosage/*therapeutic use | 2 | 40.0 |
HIV Infections/*drug therapy/mortality | 2 | 7.0 |
Prospective Studies | 28 | 0.0 |
Survival Rate | 7 | 0.0 |
DNA, Viral/*blood | 4 | 10.0 |
Evaluation Studies | 6 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Predictive Value of Tests | 4 | 0.0 |
Reagent Kits, Diagnostic | 3 | 2.0 |
Neoplasm Staging | 2 | 0.0 |
Remission Induction | 3 | 0.0 |
Genes, Viral | 5 | 2.0 |
HIV-1/genetics/*isolation & purification | 6 | 12.0 |
Magnetic Resonance Imaging | 5 | 0.0 |
AIDS-Related Complex/*drug therapy | 8 | 50.0 |
Acquired Immunodeficiency Syndrome/*drug therapy | 11 | 17.0 |
Drug Evaluation | 14 | 5.0 |
Drug Tolerance | 2 | 1.0 |
Peripheral Nervous System Diseases/chemically induced | 3 | 17.0 |
Proportional Hazards Models | 3 | 0.0 |
HIV Infections/*drug therapy/immunology/mortality | 2 | 11.0 |
Patient Compliance | 4 | 2.0 |
Prognosis | 25 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Transfection | 2 | 0.0 |
Administration, Oral | 8 | 0.0 |
CD4-Positive T-Lymphocytes | 10 | 3.0 |
HIV Infections/blood/*immunology | 2 | 3.0 |
*HIV-2 | 2 | 8.0 |
Immunologic Memory | 2 | 0.0 |
In Vitro | 13 | 0.0 |
Lymphocyte Activation | 22 | 0.0 |
T-Lymphocyte Subsets/*immunology | 2 | 0.0 |
Antigens, CD4/blood | 2 | 3.0 |
CD4-CD8 Ratio | 2 | 0.0 |
Leukocytes, Mononuclear/drug effects/*immunology | 2 | 6.0 |
beta 2-Microglobulin/metabolism | 2 | 2.0 |
CD4-Positive T-Lymphocytes/immunology | 11 | 1.0 |
Antigens, CD4/analysis | 4 | 0.0 |
Cohort Studies | 7 | 0.0 |
Drug Interactions | 3 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Clinical Protocols | 2 | 3.0 |
HIV Seropositivity/*drug therapy | 2 | 18.0 |
Cell Separation | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 4 | 0.0 |
Autoimmune Diseases/*immunology | 2 | 1.0 |
Immunoelectrophoresis, Two-Dimensional | 2 | 1.0 |
Child, Preschool | 20 | 0.0 |
AIDS-Related Complex/metabolism | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/metabolism | 2 | 15.0 |
HIV Infections/*metabolism | 2 | 4.0 |
AIDS-Related Complex/complications | 15 | 78.0 |
Cross-Sectional Studies | 4 | 0.0 |
HIV Infections/*complications | 8 | 2.0 |
Sexual Behavior | 7 | 9.0 |
Substance Abuse, Intravenous/complications | 5 | 10.0 |
Anemia/chemically induced | 2 | 18.0 |
Bisexuality | 2 | 10.0 |
Homosexuality | 48 | 32.0 |
Life Tables | 2 | 1.0 |
Safety | 4 | 2.0 |
Zidovudine/administration & dosage/adverse effects/*therapeutic use | 2 | 12.0 |
Leukocyte Count | 57 | 3.0 |
Zidovudine/*administration & dosage/adverse effects | 3 | 17.0 |
Acquired Immunodeficiency Syndrome/*complications/drug therapy | 3 | 21.0 |
Didanosine/*adverse effects | 2 | 66.0 |
Mycobacterium avium-intracellulare Infection/complications | 2 | 40.0 |
Bone Marrow/drug effects | 2 | 2.0 |
Dogs | 2 | 0.0 |
AIDS-Related Complex/prevention & control | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/prevention & control | 2 | 16.0 |
HIV Seropositivity/*blood | 3 | 10.0 |
Substance Abuse, Intravenous | 3 | 7.0 |
Psychometrics | 2 | 3.0 |
AIDS-Related Complex/blood/complications/immunology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/blood/complications/immunology | 2 | 100.0 |
Antibodies, Anti-Idiotypic/*blood/immunology | 2 | 50.0 |
Autoantibodies/*blood/immunology | 2 | 8.0 |
Immunoglobulin M/blood/immunology | 2 | 16.0 |
Immunoglobulins, Fab/*immunology | 2 | 7.0 |
Thrombocytopenia/blood/complications/immunology | 2 | 100.0 |
Diagnosis, Differential | 4 | 0.0 |
AIDS-Related Opportunistic Infections/*diagnosis | 2 | 12.0 |
DNA, Viral | 2 | 1.0 |
HIV Seropositivity/diagnosis/microbiology | 2 | 100.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Acquired Immunodeficiency Syndrome/complications | 6 | 12.0 |
Hematopoiesis | 2 | 0.0 |
*Signal Transduction | 2 | 0.0 |
Hyperplasia | 3 | 0.0 |
AIDS-Related Complex/*therapy | 5 | 100.0 |
Acquired Immunodeficiency Syndrome/*therapy | 2 | 13.0 |
Antigens, CD8/analysis | 2 | 0.0 |
Cytotoxicity, Immunologic | 4 | 0.0 |
HIV Antigens/*immunology | 2 | 3.0 |
HIV-1/genetics/*immunology | 2 | 2.0 |
Immunity, Cellular | 6 | 0.0 |
AIDS-Related Complex/*immunology | 22 | 73.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Clinical Trials | 6 | 0.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
HIV Infections/*physiopathology | 2 | 7.0 |
Didanosine/*therapeutic use | 2 | 5.0 |
Indomethacin/*pharmacology | 3 | 7.0 |
Recombinant Proteins/adverse effects/therapeutic use | 3 | 9.0 |
Acquired Immunodeficiency Syndrome/microbiology | 5 | 23.0 |
HIV Seropositivity/*microbiology | 3 | 20.0 |
Proviruses/genetics | 2 | 3.0 |
Pregnancy | 8 | 0.0 |
Acquired Immunodeficiency Syndrome/*immunology/pathology | 3 | 20.0 |
Enzyme-Linked Immunosorbent Assay | 27 | 0.0 |
HIV Infections/*immunology | 11 | 2.0 |
HIV Seropositivity/immunology | 9 | 9.0 |
AIDS-Related Complex/*complications | 6 | 85.0 |
Acquired Immunodeficiency Syndrome/*complications | 18 | 9.0 |
Nervous System Diseases/complications | 2 | 50.0 |
Pneumonia, Pneumocystis/complications | 2 | 15.0 |
Didanosine/administration & dosage/adverse effects/*therapeutic use | 2 | 20.0 |
Hematologic Diseases/chemically induced | 2 | 20.0 |
Zidovudine/*adverse effects/therapeutic use | 4 | 36.0 |
Eye Diseases/*etiology | 2 | 50.0 |
HIV Seropositivity/*complications | 2 | 2.0 |
AIDS-Related Complex/blood/complications/*drug therapy | 2 | 100.0 |
CD4-Positive T-Lymphocytes/drug effects | 3 | 5.0 |
Leukocyte Count/drug effects | 2 | 1.0 |
Chronic Disease | 2 | 0.0 |
Incidence | 9 | 0.0 |
Tomography, X-Ray Computed | 4 | 0.0 |
Fundus Oculi | 2 | 2.0 |
HIV Seropositivity | 7 | 5.0 |
Japan/epidemiology | 2 | 0.0 |
AIDS-Related Complex/blood | 4 | 57.0 |
CD4-Positive T-Lymphocytes/cytology | 2 | 2.0 |
HIV Infections/*blood | 2 | 4.0 |
HIV Seropositivity/blood | 2 | 8.0 |
Probability | 3 | 0.0 |
Acquired Immunodeficiency Syndrome/*complications/epidemiology | 2 | 40.0 |
Echocardiography | 2 | 0.0 |
Antiviral Agents/*therapeutic use | 3 | 2.0 |
Infusions, Intravenous | 5 | 0.0 |
HIV Antigens | 11 | 35.0 |
HIV-1/immunology | 5 | 6.0 |
HIV Seropositivity/*immunology | 5 | 5.0 |
Acquired Immunodeficiency Syndrome/*blood | 10 | 24.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Age Factors | 6 | 0.0 |
Combined Modality Therapy | 5 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
Sex Factors | 4 | 0.0 |
Administration, Inhalation | 3 | 1.0 |
Pentamidine/*administration & dosage | 2 | 40.0 |
Autoradiography | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
Rats, Inbred Strains | 2 | 0.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Didanosine/therapeutic use | 2 | 4.0 |
HIV Seropositivity/microbiology | 2 | 20.0 |
Multicenter Studies | 5 | 4.0 |
United States/epidemiology | 3 | 0.0 |
HIV/*drug effects | 2 | 8.0 |
Acquired Immunodeficiency Syndrome/immunology | 12 | 13.0 |
Virus Cultivation/*methods | 2 | 40.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/psychology | 2 | 50.0 |
AIDS Serodiagnosis | 2 | 14.0 |
*Hematopoiesis | 2 | 1.0 |
Neutropenia/etiology | 2 | 20.0 |
Opportunistic Infections/etiology | 3 | 60.0 |
AIDS-Related Complex/blood/*immunology | 4 | 100.0 |
Acquired Immunodeficiency Syndrome/blood/*immunology | 3 | 13.0 |
Autoantibodies/*blood | 2 | 0.0 |
HIV Seropositivity/blood/immunology | 3 | 25.0 |
Immunoglobulin G/*immunology | 2 | 2.0 |
AIDS-Related Complex/*blood | 6 | 85.0 |
HIV Antigens/blood | 4 | 25.0 |
HIV Envelope Protein gp160 | 2 | 1.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
HIV Envelope Protein gp120/immunology | 3 | 3.0 |
Immunoglobulins, Fc/immunology | 2 | 8.0 |
Atrophy | 2 | 1.0 |
Half-Life | 3 | 0.0 |
Blood Transfusion/*adverse effects | 2 | 3.0 |
CD4-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Epitopes/immunology | 2 | 0.0 |
HIV Antigens/immunology | 4 | 10.0 |
T-Lymphocytes, Helper-Inducer/immunology | 5 | 2.0 |
Hemophilia A/*complications | 10 | 25.0 |
Cytomegalovirus/immunology | 3 | 4.0 |
Fluorescent Antibody Technique | 12 | 0.0 |
Herpesvirus 4, Human/immunology | 2 | 2.0 |
Microscopy, Electron | 9 | 0.0 |
Antibodies, Monoclonal | 6 | 0.0 |
Antigens, CD/analysis | 2 | 0.0 |
Antigens, CD57 | 2 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 10 | 2.0 |
AIDS-Related Complex/immunology/*therapy | 3 | 60.0 |
HIV/*immunology | 17 | 16.0 |
beta 2-Microglobulin/analysis | 5 | 3.0 |
Platelet Count | 3 | 0.0 |
Random Allocation | 7 | 1.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Immunoglobulins/blood | 2 | 2.0 |
AIDS-Related Complex/*metabolism | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*metabolism | 3 | 21.0 |
African Continental Ancestry Group | 3 | 1.0 |
Hispanic Americans | 2 | 3.0 |
Multivariate Analysis | 3 | 0.0 |
Cytomegalovirus Infections/complications | 2 | 12.0 |
New York City/epidemiology | 3 | 8.0 |
Neuropsychological Tests | 2 | 0.0 |
Lymphocyte Subsets | 2 | 1.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
AIDS-Related Complex/microbiology | 3 | 50.0 |
HIV Seropositivity/diagnosis | 2 | 18.0 |
T-Lymphocytes, Helper-Inducer/pathology | 3 | 9.0 |
Zidovudine/adverse effects/*therapeutic use | 2 | 6.0 |
Lymph Nodes/pathology | 5 | 1.0 |
Opportunistic Infections/prevention & control | 2 | 28.0 |
Neurologic Examination | 2 | 1.0 |
Substance-Related Disorders/complications | 6 | 25.0 |
European Continental Ancestry Group | 2 | 0.0 |
Registries | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*complications/immunology | 2 | 11.0 |
Democratic Republic of the Congo | 3 | 21.0 |
Pneumonia, Pneumocystis/etiology | 2 | 50.0 |
Hemoglobins/analysis | 2 | 0.0 |
AIDS-Related Complex/*microbiology | 4 | 100.0 |
Acquired Immunodeficiency Syndrome/*microbiology | 9 | 42.0 |
Cause of Death | 2 | 1.0 |
France | 2 | 0.0 |
AIDS-Related Complex/*complications/pathology | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/*complications/pathology | 3 | 33.0 |
CD4-Positive T-Lymphocytes/pathology | 2 | 2.0 |
HIV Infections/*complications/pathology | 2 | 22.0 |
T-Lymphocytes, Suppressor-Effector/pathology | 3 | 10.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 3 | 3.0 |
Gene Products, gag/blood | 4 | 33.0 |
HIV Core Protein p24 | 18 | 23.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 7 | 4.0 |
Viral Core Proteins/blood | 4 | 30.0 |
Gene Products, gag/analysis | 4 | 17.0 |
Neutralization Tests | 7 | 1.0 |
Viral Core Proteins/analysis | 4 | 18.0 |
Acquired Immunodeficiency Syndrome/*blood/complications | 3 | 30.0 |
Antigens, CD4/immunology | 2 | 1.0 |
Receptors, Complement/immunology | 2 | 6.0 |
*Neuropsychological Tests | 3 | 9.0 |
Interleukin-1/*biosynthesis | 3 | 2.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 2 | 0.0 |
Body Composition | 2 | 0.0 |
*Energy Metabolism | 2 | 2.0 |
Rest | 2 | 4.0 |
Cell Migration Inhibition | 2 | 1.0 |
Rosette Formation | 2 | 0.0 |
HIV Antibodies/*biosynthesis | 2 | 15.0 |
HIV Antigens/*blood | 2 | 40.0 |
Maternal-Fetal Exchange | 2 | 1.0 |
Pregnancy Complications, Infectious | 2 | 11.0 |
Virus Cultivation | 2 | 4.0 |
AIDS-Related Complex/blood/immunology | 3 | 75.0 |
Acquired Immunodeficiency Syndrome/blood/immunology | 2 | 22.0 |
HIV Infections/*blood/immunology | 2 | 7.0 |
Lymphokines/*therapeutic use | 2 | 25.0 |
Attention | 2 | 10.0 |
Sick Role | 2 | 20.0 |
Injections, Intravenous | 7 | 1.0 |
Prevalence | 3 | 0.0 |
Antibodies, Antinuclear/analysis | 2 | 2.0 |
Autoantibodies/*analysis | 3 | 1.0 |
Hydrocortisone/*blood | 2 | 1.0 |
Testosterone/*blood | 2 | 0.0 |
Hematocrit | 6 | 1.0 |
Biopterin/analogs & derivatives/blood | 2 | 4.0 |
Brain/*pathology | 2 | 1.0 |
Neopterin | 2 | 2.0 |
Brain/pathology | 2 | 0.0 |
T-Lymphocyte Subsets | 2 | 1.0 |
AIDS-Related Complex/*physiopathology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*physiopathology | 3 | 21.0 |
Energy Intake | 2 | 1.0 |
Serum Albumin/analysis | 2 | 1.0 |
Weight Loss | 2 | 1.0 |
Antigens, CD8 | 4 | 1.0 |
Glycyrrhizic Acid | 2 | 33.0 |
Lymphocyte Activation/drug effects | 5 | 0.0 |
Lymphocytes/immunology | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*blood/pathology | 3 | 100.0 |
Bone Marrow/pathology | 3 | 0.0 |
Cats | 2 | 0.0 |
B-Lymphocytes/*immunology | 6 | 0.0 |
Leukocytes, Mononuclear/*immunology | 2 | 1.0 |
*Lymphocyte Activation | 7 | 0.0 |
Lymphocyte Culture Test, Mixed | 4 | 0.0 |
Pokeweed Mitogens/pharmacology | 3 | 3.0 |
Ribonucleosides/*therapeutic use | 2 | 28.0 |
AIDS-Related Complex/*drug therapy/enzymology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/enzymology | 2 | 100.0 |
Adenosine Deaminase/*blood | 3 | 27.0 |
HIV-1/*drug effects | 2 | 1.0 |
Zidovudine/administration & dosage/*adverse effects | 2 | 40.0 |
Antigens, CD3 | 2 | 0.0 |
Phenotype | 8 | 0.0 |
Fibronectins/*blood | 2 | 7.0 |
AIDS-Related Complex/epidemiology | 4 | 80.0 |
Blotting, Western | 7 | 0.0 |
Zidovudine/pharmacokinetics/*pharmacology/therapeutic use | 2 | 100.0 |
Randomized Controlled Trials | 3 | 0.0 |
HIV Antigens/analysis | 7 | 18.0 |
Adjuvants, Immunologic/*therapeutic use | 2 | 2.0 |
Acquired Immunodeficiency Syndrome/immunology/*pathology | 4 | 40.0 |
Cell Count | 2 | 0.0 |
Colony-Forming Units Assay | 4 | 0.0 |
Erythropoietin/pharmacology | 2 | 1.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Prolactin/blood | 2 | 0.0 |
Receptors, Androgen/*analysis | 2 | 3.0 |
Testosterone/blood | 2 | 0.0 |
Antigens, Viral/*immunology | 3 | 3.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Interleukin-2/biosynthesis | 3 | 0.0 |
United States | 2 | 0.0 |
HIV Antigens/*analysis | 2 | 13.0 |
T-Lymphocytes/immunology | 15 | 1.0 |
AIDS-Related Complex/immunology/*pathology | 2 | 50.0 |
Cell Division/drug effects | 2 | 0.0 |
Mitogens/pharmacology | 2 | 0.0 |
Gene Products, gag/immunology | 2 | 6.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Viral Core Proteins/immunology | 5 | 21.0 |
HIV Seropositivity/complications | 2 | 6.0 |
Immune Tolerance | 3 | 1.0 |
HIV Antibodies/immunology | 2 | 3.0 |
AIDS-Related Complex/*psychology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*psychology | 2 | 25.0 |
*Immunization, Passive | 4 | 7.0 |
AIDS-Related Complex/blood/immunology/*therapy | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/blood/immunology/*therapy | 3 | 60.0 |
HIV Antibodies/analysis | 3 | 6.0 |
Electrophysiology | 4 | 0.0 |
Phagocytosis | 2 | 0.0 |
Opportunistic Infections/immunology | 2 | 33.0 |
Reaction Time | 2 | 1.0 |
*HIV Seropositivity | 2 | 6.0 |
Hemophilia A/*therapy | 2 | 22.0 |
Memory | 2 | 10.0 |
AIDS-Related Complex/drug therapy | 2 | 25.0 |
AIDS-Related Complex/*blood/immunology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/*blood/immunology | 3 | 15.0 |
AIDS-Related Complex/*etiology | 2 | 100.0 |
HIV Seropositivity/*transmission | 2 | 40.0 |
Hypersensitivity, Delayed | 2 | 3.0 |
Retroviridae Proteins/analysis | 5 | 41.0 |
Epidemiologic Methods | 3 | 5.0 |
HIV Seropositivity/*epidemiology | 2 | 15.0 |
Marriage | 3 | 13.0 |
Substance-Related Disorders | 4 | 19.0 |
Antibody Formation | 3 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Blood Transfusion/adverse effects | 5 | 13.0 |
Acquired Immunodeficiency Syndrome/*diagnosis/immunology | 4 | 44.0 |
DNA, Recombinant | 2 | 1.0 |
Acquired Immunodeficiency Syndrome/complications/*pathology | 3 | 50.0 |
Acquired Immunodeficiency Syndrome/complications/*physiopathology | 2 | 50.0 |
Cardiolipins/*immunology | 2 | 16.0 |
*Homosexuality | 9 | 22.0 |
Virus Replication | 2 | 0.0 |
AIDS-Related Complex/pathology | 3 | 100.0 |
Acquired Immunodeficiency Syndrome/*pathology | 9 | 47.0 |
Zalcitabine | 2 | 33.0 |
HIV/isolation & purification | 2 | 6.0 |
AIDS-Related Complex/complications/*immunology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/complications/*immunology | 2 | 8.0 |
New York City | 3 | 10.0 |
Recurrence | 2 | 0.0 |
Retroviridae Proteins/immunology | 5 | 35.0 |
Viral Envelope Proteins/immunology | 5 | 20.0 |
Acquired Immunodeficiency Syndrome/complications/drug therapy | 2 | 20.0 |
*Blood Transfusion | 2 | 1.0 |
Blood Cell Count | 2 | 0.0 |
Blood Transfusion | 4 | 2.0 |
Composite Resins/*chemistry/radiation effects | 2 | 100.0 |
Dental Restoration, Permanent/*instrumentation | 2 | 100.0 |
Cell Membrane/immunology | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/immunology/*therapy | 3 | 27.0 |
Interferon Type II/*biosynthesis | 2 | 1.0 |
Phytohemagglutinins/pharmacology | 5 | 0.0 |
Stimulation, Chemical | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*epidemiology | 2 | 12.0 |
Netherlands | 2 | 1.0 |
Antiviral Agents/adverse effects/*therapeutic use | 2 | 8.0 |
Ditiocarb/administration & dosage/adverse effects/*therapeutic use | 2 | 100.0 |
AIDS-Related Complex/diagnosis/immunology | 2 | 66.0 |
Disease Susceptibility | 2 | 0.0 |
Immunoglobulin A/analysis | 2 | 1.0 |
Immunoglobulin M/analysis | 5 | 2.0 |
Acquired Immunodeficiency Syndrome/immunology/microbiology/*therapy | 2 | 100.0 |
Italy | 3 | 0.0 |
Postoperative Complications/therapy | 2 | 33.0 |
*Enzyme-Linked Immunosorbent Assay | 2 | 2.0 |
HIV Envelope Protein gp41 | 2 | 50.0 |
Acquired Immunodeficiency Syndrome/*etiology | 2 | 14.0 |
Cell Aggregation | 2 | 1.0 |
Chemotaxis, Leukocyte | 2 | 1.0 |
beta 2-Microglobulin/*metabolism | 2 | 4.0 |
5'-Nucleotidase | 4 | 18.0 |
Lymphocytes/classification | 3 | 10.0 |
Nucleoside Deaminases/*blood | 2 | 40.0 |
Acquired Immunodeficiency Syndrome/*diagnosis | 3 | 15.0 |
Antibodies, Viral/analysis | 22 | 21.0 |
HIV Antibodies | 28 | 46.0 |
Binding, Competitive | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
B-Lymphocytes | 2 | 1.0 |
T-Lymphocytes, Helper-Inducer | 2 | 6.0 |
T-Lymphocytes, Suppressor-Effector | 2 | 5.0 |
AIDS-Related Complex/complications/*pathology | 2 | 100.0 |
Cytomegalovirus Infections/complications/pathology | 2 | 100.0 |
Immunotherapy | 3 | 0.0 |
Antibodies, Viral/*analysis | 23 | 35.0 |
Antigens, Viral/analysis | 6 | 7.0 |
HIV/immunology | 12 | 21.0 |
Antigens, Viral/immunology | 4 | 3.0 |
Leukocytes/immunology | 2 | 1.0 |
Antibodies, Viral/immunology | 7 | 8.0 |
Retroviridae Proteins/*immunology | 3 | 50.0 |
Viral Envelope Proteins/*immunology | 4 | 10.0 |
Antigens, Viral/*analysis | 6 | 12.0 |
*Acquired Immunodeficiency Syndrome | 2 | 28.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
AIDS-Related Complex/etiology/immunology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/etiology/*immunology | 2 | 20.0 |
HIV/drug effects | 2 | 10.0 |
Zidovudine | 2 | 20.0 |
*Plasmapheresis | 2 | 6.0 |
Immunoglobulins/analysis | 4 | 1.0 |
Lymphocytes/cytology/immunology | 2 | 8.0 |
Semen/immunology | 2 | 13.0 |
Killer Cells, Natural/*immunology | 3 | 0.0 |
Cytotoxicity Tests, Immunologic | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/immunology/microbiology | 2 | 66.0 |
Lymphocytes/classification/immunology | 2 | 16.0 |
Antigen-Antibody Complex/*analysis | 3 | 1.0 |
RNA-Directed DNA Polymerase/analysis | 3 | 11.0 |
Substance-Related Disorders/immunology | 3 | 75.0 |
HIV/*isolation & purification | 4 | 16.0 |
Hemophilia A/complications | 3 | 17.0 |
Antigens, Surface/analysis | 4 | 0.0 |
Monocytes/*immunology | 4 | 0.0 |
Hemophilia A/*complications/immunology | 2 | 28.0 |
AIDS-Related Complex/*pathology | 2 | 50.0 |
Bone Marrow Cells | 2 | 0.0 |
Deltaretrovirus/*immunology | 13 | 68.0 |
Lymphocytes | 2 | 1.0 |
Antigens, Surface/*analysis | 3 | 1.0 |
HLA-DR Antigens/analysis | 2 | 0.0 |
Lymphocyte Activation/*drug effects | 3 | 0.0 |
Thymosin/*analogs & derivatives/pharmacology | 2 | 25.0 |
Complement Activation | 2 | 0.0 |
Receptors, Complement 3b | 4 | 1.0 |
Acquired Immunodeficiency Syndrome/epidemiology/*etiology/immunology | 2 | 40.0 |
Injections, Intravenous/adverse effects | 2 | 100.0 |
Risk | 16 | 1.0 |
*Aging | 2 | 1.0 |
Heart Rate | 3 | 1.0 |
Antibodies, Viral/*immunology | 3 | 7.0 |
Gene Products, gag | 3 | 30.0 |
Blood Component Removal | 2 | 4.0 |
T-Lymphocytes/classification | 5 | 15.0 |
Hemophilia A/microbiology | 2 | 66.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Interleukin-2/*immunology | 2 | 3.0 |
Receptors, Interleukin-2 | 3 | 2.0 |
Acquired Immunodeficiency Syndrome/immunology/*microbiology | 2 | 25.0 |
Histocytochemistry | 2 | 0.0 |
Leukocytes/*immunology | 2 | 1.0 |
*Gene Expression Regulation | 3 | 0.0 |
Antigens, Differentiation, T-Lymphocyte | 6 | 2.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Lymphocytes/*immunology | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 2 | 0.0 |
Sarcoma, Kaposi/pathology | 2 | 33.0 |
T-Lymphocytes/drug effects/immunology | 2 | 2.0 |
Virus Replication/drug effects | 2 | 0.0 |
Methods | 2 | 0.0 |
Concanavalin A/pharmacology | 3 | 1.0 |
Deltaretrovirus/immunology | 4 | 44.0 |
Blood Donors | 2 | 0.0 |
Immunosorbent Techniques | 2 | 0.0 |
Interleukin-2/immunology | 2 | 1.0 |
Antigens, Viral/genetics/*immunology | 2 | 18.0 |
Acquired Immunodeficiency Syndrome/*immunology/microbiology | 3 | 60.0 |
Bone Marrow/microbiology | 2 | 40.0 |
Molecular Weight | 4 | 0.0 |
Saliva/microbiology | 2 | 33.0 |
Viral Proteins/analysis | 4 | 17.0 |
Immune Sera | 2 | 0.0 |
Skin Tests | 4 | 2.0 |
Lymphocytes/microbiology | 2 | 13.0 |
Monocytes/microbiology | 2 | 12.0 |
HLA-DR Antigens | 2 | 0.0 |
C-Reactive Protein/analysis | 2 | 0.0 |
Lymphatic Diseases/*immunology | 4 | 66.0 |
Cytopathogenic Effect, Viral | 2 | 1.0 |
Cell Differentiation | 2 | 0.0 |
Deltaretrovirus/*isolation & purification | 4 | 80.0 |
Prostitution | 2 | 11.0 |
Lymphatic Diseases/immunology | 2 | 25.0 |
Culture Media | 2 | 0.0 |
Marginal Adaptation (Dentistry) | 2 | 50.0 |
Sarcoma, Kaposi/immunology | 2 | 25.0 |
Deltaretrovirus/*genetics | 2 | 40.0 |
Blood Pressure | 2 | 0.0 |
Pressoreceptors/physiopathology | 2 | 28.0 |
Vagus Nerve/physiopathology | 2 | 25.0 |
Phylogeny | 2 | 0.0 |
*Dental Bonding | 4 | 25.0 |
Dental Debonding | 2 | 100.0 |
Shear Strength | 2 | 40.0 |
Radiation Dosage | 2 | 2.0 |
Sympathetic Nervous System/physiopathology | 2 | 8.0 |
Bisphenol A-Glycidyl Methacrylate/chemistry | 2 | 66.0 |
Methacrylates/chemistry | 3 | 42.0 |
Polyethylene Glycols/chemistry | 2 | 12.0 |
Polymethacrylic Acids/chemistry | 2 | 66.0 |
